logo image
search icon
Plasma Fractionation Market

Plasma Fractionation Market Size, Share & Trends Analysis Report By Product (Immune-Globulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, Other Plasma Products), By Application, By End-User, By Region, And By Segment Forecasts, 2024-2031

Report ID : 2140 | Published : 2024-05-28 | Pages: 179 | Format: PDF/EXCEL

Plasma Fractionation Market Size is valued at USD 4.2 Bn in 2023 and is predicted to reach USD 8.9 Bn by the year 2031 at a 10.1 % CAGR during the forecast period for 2024-2031.

Key Industry Insights & Findings from the Report:

  • The demand for plasma-derived therapies has been increasing due to the rising prevalence of immune deficiencies, respiratory infections, including other disorders.
  • Increased awareness and improved diagnostic services have led to more accurate identification and diagnosis of rare diseases, which is resulting in driving industry growth.
  • North America ruled the market and accounted for a revenue share of global revenue in 2023.
  • One of the major concerns restraining industry growth is stringent regulatory requirements and complex approval processes for plasma-derived products.

 plasma fractionation

Plasma fractionation is an important technique in medicine and biotechnology, particularly in manufacturing numerous medicinal compounds generated from human blood plasma. It entails separating and isolating various components found in blood plasma to produce specialized medicinal products. The increased incidence of senior people around the world, who are more prone to rare conditions that necessitate the use of blood derivatives, is a primary driver of the market's rise. Furthermore, the rising use of immunoglobulins and alpha-1-antitrypsin in numerous departments of medicine worldwide is expected to fuel market expansion. Moreover, the growth of this market is influenced by the increase in blood-collecting facilities around the world.

However, lockdowns, social distancing measures, and fears of viral transmission hampered plasma collection from willing donors during the COVID-19 pandemic. Despite the devastating impact of the current coronavirus pandemic on some enterprises, the worldwide sector has risen tremendously in recent years. As the COVID-19 pandemic peaked, more people were negatively affected by the viral infection, necessitating the use of plasma as a treatment.

Competitive Landscape

Some Major Key Players In The Plasma Fractionation Market:

  • CSL (Australia)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Grifols, S.A. (Spain)
  • Octapharma AG (Switzerland)
  • Kedrion S.P.A (Italy)
  • LFB (France)
  • ADMA Biologics (US)
  • Sanquin (Netherlands)
  • China Biologic Products Holdings Inc. (China)
  • GC Pharma (Korea)
  • Hualan Bioengineering Co., Ltd. (China)
  • Japan Blood Products Organization (Japan)
  • Emergent BioSolutions (US)
  • Shanghai Raas Blood Products Co., Ltd. (China)
  • Intas Pharmaceuticals Ltd. (India)
  • Bharat Serum Vaccines Limited (India)
  • SK Plasma (Korea)
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Kamada (Israel)
  • Centurion Pharma (Istanbul)
  • Prothya Biosolutions (Netherlands)
  • PlasmaGen BioSciences Pvt. Ltd. (India)
  • Virchow Biotech Private Limited (India)
  • Fusion Healthcare (India)
  • Hemarus Therapeutics Limited (India)
  • Others

Market Segmentation:

The Plasma Fractionation Market consists of Product, application, and end-user segments. As per the product, the market is segmented as immune-globulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The immune-globulins segment includes intravenous immune globulins, subcutaneous immune globulins, and other immune globulins. By coagulation factor concentrates, the market is segmented into Von Willebrand factor, Factor VIII, Factor IX, prothrombin complex concentrate, fibrinogen concentrates, Factor XIII, and others. The applications segment includes neurology, immunology, haematology, critical care, pulmonology, hemato-oncology, rheumatology, and others. The end-user segment includes hospitals & clinics, clinical research laboratories, and academic institutes.

Based On Product, The Immune-Globulins Segment Is Accounted As A Major Contributor In The Plasma Fractionation Market. 

The immune-globulins category is expected to hold a major share in the global Plasma Fractionation Market in 2022. The enormous demand for IVIG treatments for primary and secondary immunodeficiency illnesses explains the company's supremacy. The rising prevalence of such diseases, combined with advancements in treatment, has resulted in a surge in demand for intravenous immunoglobulin. Significant product launches by prominent market players also contribute to the growth of the coagulation factors category. Immunoglobulin therapy is increasingly used to treat diseases other than immunodeficiency disorders. It is used to treat autoimmune diseases, neurological disorders, and inflammatory ailments, which increases its market potential.

The Hospitals & Clinics Segment Witnessed Growth At A Rapid Rate.

The hospitals & clinics segment is probable to grow at a rapid rate in the global Plasma Fractionation Market. The segment is expected to rise significantly due to increased off-label use of plasma fractionation products in hospitals to treat a number of disorders, improved infrastructure, and a rise in healthcare services provided by hospitals. Furthermore, plasma fractionation products are in high demand for complicated illnesses that can be addressed in modern therapeutic settings.

In The Region, The Asia Pacific Plasma Fractionation Market Holds A Significant Revenue Share.

The Asia Pacific Plasma Fractionation Market is expected to register the maximum market share in terms of revenue in the near future. This is due to growing knowledge of the multiple benefits of plasma, as well as an increase in the prevalence of respiratory illnesses. Furthermore, the presence of important players, an increase in the count of plasma collection facilities, an increase in immunoglobulin consumption, and the capacity to deliver plasma due to plasma collection and distribution viability all contribute to the regional market's growth.

As a result of favourable government regulations, increased public and private funding for research and development, increased use of immunoglobulins, rising prevalence of target diseases with an ageing population with blood-related diseases, and rising plasma-based treatment adoption, the plasma fractionation market is expanding.

Recent Developments:

  • In March 2023, Takeda made an investment of 100 billion JPY in the establishment of a novel manufacturing facility in Japan, specifically dedicated to the production of plasma-derived medicines. The investment made by Takeda exemplified the company's dedication to prioritising patients and fulfilling its obligations in relation to its patient-centric, people-oriented, and environmentally conscious objectives. This approach was supported by the utilisation of data and digital technologies.
  • In Dec 2022, CSL has recently inaugurated its Plasma Fractionation Facility in Victoria, Australia, which represents a significant milestone in the country's plasma manufacturing sector. With a staggering investment of $900 Bn, this state-of-the-art facility stands as the largest of its type in the Southern Hemisphere. The aforementioned statement pertains to a capital investment programme of over $2 billion that CSL is presently implementing in Australia.

Plasma Fractionation Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2023

USD 4.2Bn

Revenue Forecast In 2031

USD 8.9 Bn

Growth Rate CAGR

CAGR of 10.1 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Product, application, and end-user

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

CSL (Australia), Takeda Pharmaceutical company limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), LFB (France), ADMA Biologics (US), Sanquin (Netherlands), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Hualan Bioengineering Co., Ltd. (China), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), Shanghai Raas Blood Products Co., Ltd. (China), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), Kamada (Israel), Centurion Pharma (Istanbul), Prothya Biosolutions (Netherlands), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and Hemarus Therapeutics Limited (India)

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Plasma Fractionation Market Snapshot

Chapter 4. Global Plasma Fractionation Market Variables, Trends & Scope

4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Application Estimates & Trend Analysis
5.1. By Application, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Application:

5.2.1. Neurology
5.2.2. Immunology
5.2.3. Hematology
5.2.4. Critical Care
5.2.5. Pulmonology
5.2.6. Hemato-Oncology
5.2.7. Rheumatology
5.2.8. Others

Chapter 6. Market Segmentation 2: By Product Estimates & Trend Analysis
6.1. By Product & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Product:

6.2.1. Immune-Globulins

6.2.1.1. Intravenous Immune-Globulins
6.2.1.2. Subcutaneous Immune-Globulins
6.2.1.3. Other Immune-Globulins

6.2.2. Coagulation Factor Concentrates

6.2.2.1. Factor VIII
6.2.2.2. Factor IX
6.2.2.3. Von Willebrand Factor
6.2.2.4. Prothrombin Complex Concentrate
6.2.2.5. Fibrinogen Concentrates
6.2.2.6. Factor XIII
6.2.2.7. Others

6.2.3. Albumin
6.2.4. Protease Inhibitors
6.2.5. Other Plasma Products 

Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channel:

7.2.1. Hospitals & Clinics
7.2.2. Clinical Research Laboratories
7.2.3. Academic Institutes 

Chapter 8. Plasma Fractionation Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Plasma Fractionation Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031
8.1.2. North America Plasma Fractionation Market revenue (US$ Million) estimates and forecasts By Product, 2019-2031
8.1.3. North America Plasma Fractionation Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
8.1.4. North America Plasma Fractionation Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe Plasma Fractionation Market revenue (US$ Million) By Application, 2019-2031
8.2.2. Europe Plasma Fractionation Market revenue (US$ Million) By Product, 2019-2031
8.2.3. Europe Plasma Fractionation Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.2.4. Europe Plasma Fractionation Market revenue (US$ Million) by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Plasma Fractionation Market revenue (US$ Million) By Application, 2019-2031
8.3.2. Asia Pacific Plasma Fractionation Market revenue (US$ Million) By Product, 2019-2031
8.3.3. Asia Pacific Plasma Fractionation Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.3.4. Asia Pacific Plasma Fractionation Market revenue (US$ Million) by country, 2019-2031

8.4. Latin America

8.4.1. Latin America Plasma Fractionation Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
8.4.2. Latin America Plasma Fractionation Market revenue (US$ Million) By Product, (US$ Million) 2019-2031
8.4.3. Latin America Plasma Fractionation Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.4.4. Latin America Plasma Fractionation Market revenue (US$ Million) by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Plasma Fractionation Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
8.5.2. Middle East & Africa Plasma Fractionation Market revenue (US$ Million) By Product, (US$ Million) 2019-2031
8.5.3. Middle East & Africa Plasma Fractionation Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.5.4. Middle East & Africa Plasma Fractionation Market revenue (US$ Million) by country, 2019-2031

Segmentation of Plasma Fractionation Market-

Plasma Fractionation Market By Product-

  • Immune-Globulins
    • Intravenous Immune-Globulins
    • Subcutaneous Immune-Globulins
    • Other Immune-Globulins
  • Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Von Willebrand Factor
    • Prothrombin Complex Concentrate
    • Fibrinogen Concentrates
    • Factor XIII
    • Others
  • Albumin
  • Protease Inhibitors
  • Other Plasma Products

 Plasma fractionation

Plasma Fractionation Market By Application-

  • Neurology
  • Immunology
  • Hematology
  • Critical Care
  • Pulmonology
  • Hemato-Oncology
  • Rheumatology
  • Others

Plasma Fractionation Market By End-User-

  • Hospitals & Clinics
  • Clinical Research Laboratories
  • Academic Institutes

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • The rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Plasma Fractionation Market Size?

Plasma Fractionation Market is expected to grow at a 10.1% CAGR during the forecast period for 2024-2031.

Prothya Biosolutions (Netherlands), PlasmaGen BioSciences Pvt. Ltd. (India), Virchow Biotech Private Limited (India), Fusion Healthcare (India), and O

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Biotechnology

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach